selectivity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
=== 1990s === In 1992, the company acquired, then merged with, the Adelaide pathology practice Clinpath Laboratories. In 1994, Sonic Healthcare acquired and merged with Sydney's Tan Pathology. In 1995, Sonic Healthcare acquired the Adelaide practice Pathlab making it part of Clinpath Laboratories. The company also formally changed from Sonic Technology to Sonic Healthcare Limited. In 1996, Sonic Healthcare acquired New South Wales-based companies Hanly Moir Pathology and Barratt and Smith Pathologists, and Canberra-based Barratt Smith Moran Pathology. Douglass Laboratories merged operations with Hanly Moir Pathology to form Douglass Hanly Moir Pathology. Sonic Clinical Trials began operating from the Douglass Hanly Moir Pathology site at North Ryde. Sonic Healthcare became Australia's largest pathology group. In 1998, it acquired the SGS Medical Group: Sullivan Nicolaides Pathology (Queensland), Northern Pathology (Queensland), Melbourne Pathology (Victoria), Diagnostic Services (Tasmania), Diagnostic Medical Laboratories (New Zealand), Medlab Central (New Zealand), Medlab South (New Zealand), Valley Diagnostic Laboratories (New Zealand), and the New Zealand Radiology Group. This created the largest diagnostic group in Australasia and began the company's diagnostic imaging. In January 1999, Sonic Healthcare acquired two pathology operations from Alpha Healthcare: Australian Diagnostics Laboratories in Sydney and Southern Pathology on the south coast of New South Wales (NSW).
== Medical uses == The most common indication for butorphanol is management of migraine using the intranasal spray formulation. It may also be used parenterally for management of moderate-to-severe pain, as a supplement for balanced general anesthesia, and management of pain during labor. Butorphanol is also quite effective at reducing post-operative shivering (owing to its kappa agonist activity). Butorphanol is more effective in reducing pain in women than in men.
=== Impaired wound healing === Individuals taking sirolimus are at increased risk of experiencing impaired or delayed wound healing, particularly if they have a body mass index more than 30 kg/m2 (classified as obese).
Sources: en.wikipedia.org
== Prevention == Many types of dwarfism are currently impossible to prevent because they are genetically caused. Genetic conditions that cause dwarfism may be identified with genetic testing, by screening for the specific variations that result in the condition. However, due to the number of causes of dwarfism, it may be impossible to determine definitively if a child will be born with dwarfism. Dwarfism resulting from malnutrition or a hormonal abnormality may be treated with an appropriate diet or hormonal therapy. Growth hormone deficiency may be remedied via injections of human growth hormone during childhood.
11B is more sensitive than 10B and yields sharper signals. The nuclear spin of 10B is 3 and that of 11B is 3/2. Quartz tubes must be used because borosilicate glass interferes with measurement. 13C, a spin-1/2 nucleus, is widely used, despite its relative paucity in naturally occurring carbon (approximately 1.1%). It is stable to nuclear decay. Since there is a low percentage in natural carbon, spectrum acquisition on samples which have not been enriched in 13C takes a long time. Frequently used for labeling of compounds in synthetic and metabolic studies. Has low sensitivity and moderately wide chemical shift range, yields sharp signals. Low percentage makes it useful by preventing spin–spin couplings and makes the spectrum appear less crowded. Slow relaxation of 13C not bonded to hydrogen means that spectra are not integrable unless long acquisition times are used. 14N, spin-1, is a medium sensitivity nucleus with wide chemical shift range. Its large quadrupole moment interferes with acquisition of high-resolution spectra, limiting usefulness to smaller molecules and functional groups with a high degree of symmetry such as in the head-groups of lipids. 15N, spin-1/2, is relatively commonly used. Can be used for isotopically labeling compounds. Very insensitive but yields sharp signals. Low percentage in natural nitrogen together with low sensitivity requires high concentrations or expensive isotope enrichment. 17O, spin-5/2, low sensitivity and very low natural abundance (0.037%), wide chemical shift range (up to 2000 ppm).
=== Side effects === Despite its usefulness in experimental studies, 2,6-DCBQ is considered a highly toxic compound, especially as an environmental contaminant formed during the chlorination of drinking water. The primary reason for its toxicity is the generation of reactive oxygen species (ROS), which leads to oxidative stress in cells. This oxidative stress can damage proteins, lipids, DNA, and can also disrupt mitochondrial function, reducing cellular energy production and promoting apoptosis. Exposure to 2,6-DCBQ has been linked to several adverse biological effects. These include neurotoxicity, where the neuronal cell survival and differentiation is impaired, as well as genotoxic effects such as DNA damage and activation of cell-cycle control pathways. Studies in animals have also shown potential kidney damage and inflammatory responses in tissues. Due to its harmful side effects and its presence as a disinfection by-product, 2,6-DCBQ is considered a compound of concern in environmental and toxicological research.
Cats are natural carnivores and require high amounts of protein in the diet. Since kittens are in a growth phase, they need substantial levels of protein to supply essential amino acids for the development of tissues and muscles. It is recommended that kittens consume a diet containing approximately 30% protein, on a dry matter basis, for proper growth. Taurine is an essential amino acid found only in animal tissue; the mother cat cannot produce enough of it for her kittens. As it is an indispensable amino acid, it must be provided exogenously through the diet at 10 mg per kg of bodyweight, each day. Taurine deficiency can lead to poor growth in kittens, and it can cause retinal degeneration in cats.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
Keep the powder dry, protected from light, and at minus 20 degrees Celsius or lower. A desiccant and a sealed vial limit moisture uptake. Let the vial reach room temperature before opening to reduce condensation.